Junco Shibayama Warren

Dr. Junco Shibayama Warren

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TKToshihide Kashihara
Toshihide Kashihara
RMRisa Mukai Mukai
Risa Mukai Mukai
Shinichi OkaShinichi Oka
Shinichi Oka
PZPeiyong Zhai
Peiyong Zhai
YNYasuki Nakada
Yasuki Nakada
JSJunichi Sadoshima
Junichi Sadoshima
The heart utilizes multiple adaptive mechanisms to maintain pump function. Compensatory cardiac hypertrophy reduces wall stress and oxygen consumption, thereby protecting the heart against acute blood pressure elevation. The nuclear effector of the Hippo pathway, Yes-associated protein 1 (YAP), is activated and mediates compensatory cardiac hypertrophy in response to acute pressure overload (PO). In this study, YAP promoted glycolysis by upregulating glucose transporter 1 (GLUT1), which in turn caused accumulation of intermediates and metabolites of the glycolytic, auxiliary, and anaplerotic pathways during acute PO. Cardiac hypertrophy was inhibited and heart failure was exacerbated in mice with YAP haploinsufficiency in the presence of acute PO. However, normalization of GLUT1 rescued the detrimental phenotype. PO induced the accumulation of glycolytic metabolites, including l-serine, l-aspartate, and malate, in a YAP-dependent manner, thereby promoting cardiac hypertrophy. YAP upregulated the GLUT1 gene through interaction with TEA domain family member 1 (TEAD1) and HIF-1α in cardiomyocytes. Thus, YAP induces compensatory cardiac hypertrophy through activation of the Warburg effect.

30 July 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JWJunco Shibayama Warren
Junco Shibayama Warren
CTChristopher M. Tracy
Christopher M. Tracy
MMMickey R. Miller
Mickey R. Miller
AMAman Makaju
Aman Makaju
MSMarta W. Szulik
Marta W. Szulik
SFSarah Franklin
Sarah Franklin
Significance: Smyd1 is a muscle-specific histone methyltransferase, and its role in the regulation of growth and differentiation in skeletal and cardiac muscle is well established. However, despite the persistent expression of Smyd1 in postnatal cardiomyocytes, the role of Smyd1 in the adult heart is largely unknown. We show that Smyd1 regulates energy metabolism in the heart. Cardiac-specific ablation of Smyd1 in the mouse adult heart resulted in global downregulation of mitochondrial proteins involved in oxidative phosphorylation, concurrent with reduced mitochondrial respiration capacity. We further demonstrate that the regulation of Smyd1 in metabolism is through transcriptional control of PGC-1α, a key regulator of mitochondrial energetics. Thus, our data reveal a role for Smyd1 as a master regulator of cardiac energetics.

30 January 2020 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
SOShin-Ichi Oka
Shin-Ichi Oka
ASAmira D. Sabry
Amira D. Sabry
KCKeiko M. Cawley
Keiko M. Cawley
JWJunco Shibayama Warren
Junco Shibayama Warren
Metabolic adaption is crucial for the heart to sustain its contractile activity under various physiological and pathological conditions. At the molecular level, the changes in energy demand impinge on the expression of genes encoding for metabolic enzymes. Among the major components of an intricate transcriptional circuitry, peroxisome proliferator-activated receptor γ coactivator 1 alpha (PGC-1α) plays a critical role as a metabolic sensor, which is responsible for the fine-tuning of transcriptional responses to a plethora of stimuli. Cumulative evidence suggests that energetic impairment in heart failure is largely attributed to the dysregulation of PGC-1α. In this review, we summarize recent studies revealing how PGC-1α is regulated by a multitude of mechanisms, operating at different regulatory levels, which include epigenetic regulation, the expression of variants, post-transcriptional inhibition, and post-translational modifications. We further discuss how the PGC-1α regulatory cascade can be impaired in the failing heart.

1 September 2017 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Closed access
PDF file
JWJunco Shibayama Warren
Junco Shibayama Warren
SOShin-Ichi Oka
Shin-Ichi Oka
DZDaniela Zablocki
Daniela Zablocki
JSJunichi Sadoshima
Junichi Sadoshima
Studies using omics-based approaches have advanced our knowledge of metabolic remodeling in cardiac hypertrophy and failure. Metabolomic analysis of the failing heart has revealed global changes in mitochondrial substrate metabolism. Peroxisome proliferator-activated receptor-α (PPARα) plays a critical role in synergistic regulation of cardiac metabolism through transcriptional control. Metabolic reprogramming via PPARα signaling in heart failure ultimately propagates into myocardial energetics. However, emerging evidence suggests that the expression level of PPARα per se does not always explain the energetic state in the heart. The transcriptional activities of PPARα are dynamic, yet highly coordinated. An additional level of complexity in the PPARα regulatory mechanism arises from its ability to interact with various partners, which ultimately determines the metabolic phenotype of the diseased heart. This review summarizes our current knowledge of the PPARα regulatory mechanisms in cardiac metabolism and the possible role of PPARα in epigenetic modifications in the diseased heart. In addition, we discuss how metabolomics can contribute to a better understanding of the role of PPARα in the progression of cardiac hypertrophy and failure.

30 April 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
SOShin-Ichi Oka
Shin-Ichi Oka
JBJaemin Byun
Jaemin Byun
CHChun-Yang Huang
Chun-Yang Huang
NINobushige Imai
Nobushige Imai
GRGuersom Ralda
Guersom Ralda
JSJunichi Sadoshima
Junichi Sadoshima
Rationale: Diabetic cardiomyopathy is accompanied by increased production of NADH, predominantly through oxidation of fatty acids and consequent increases in oxidative stress. The role of Nampt (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme of the salvage pathway of nicotinamide adenine dinucleotide synthesis, in the development of diabetic cardiomyopathy is poorly understood. Objective: We investigated the role of endogenous and exogenous Nampt during the development of diabetic cardiomyopathy in response to high-fat diet (HFD) consumption and in the context of oxidative stress. Methods and Results: HFD consumption upregulated endogenous Nampt, and HFD-induced cardiac diastolic dysfunction, fibrosis, apoptosis, and proinflammatory signaling were alleviated in transgenic mice with cardiac-specific overexpression of Nampt. The alleviation of diastolic dysfunction observed in these mice was abolished by inhibition of NADP(H) production via NADK (NAD kinase) inhibition. Nampt overexpression decreased oxidation of GSH (glutathione) and Trx1 (thioredoxin 1) targets, dityrosine, and the accumulation of toxic lipids, including ceramides and diglycerides, in the presence of HFD consumption. Nampt overexpression upregulated not only NAD + (nicotinamide adenine dinucleotide) but also NADP + (nicotinamide adenine dinucleotide phosphate) and NADPH in the heart and in cultured cardiomyocytes, which, in turn, stimulated the glutathione and Trx1 systems and alleviated oxidative stress in the heart induced by HFD consumption. In cultured cardiomyocytes, Nampt-induced upregulation of NADPH was abolished in the presence of NADK knockdown, whereas that of NAD + was not. Nampt overexpression attenuated H 2 O 2 -induced oxidative inhibition of Prdx1 (peroxiredoxin 1) and mTOR (mammalian target of rapamycin) in an NADK-dependent manner in cultured cardiomyocytes. Nampt overexpression also attenuated H 2 O 2 -induced cell death, an effect that was partly abolished by inhibition of NADK, Trx1, or glutathione synthesis. In contrast, oxidative stress and the development of diabetic cardiomyopathy in response to HFD consumption were exacerbated in Nampt heterozygous knockout (Nampt +/− ) mice. Conclusions: Nampt-mediated production of NAD + protects against oxidative stress, in part, through the NADPH-dependent reducing system, thereby alleviating the development of diabetic cardiomyopathy in response to HFD consumption.

23 June 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SOShin-Ichi Oka
Shin-Ichi Oka
ASAmira D. Sabry
Amira D. Sabry
AHAmanda K. Horiuchi
Amanda K. Horiuchi
KCKeiko M. Cawley
Keiko M. Cawley
SOSean A. O’vEry
Sean A. O’vEry
JWJunco Shibayama Warren
Junco Shibayama Warren
The transcriptional regulatory machinery in mitochondrial bioenergetics is complex and is still not completely understood. We previously demonstrated that the histone methyltransferase Smyd1 regulates mitochondrial energetics. Here, we identified Perm1 (PPARGC-1 and ESRR-induced regulator, muscle specific 1) as a downstream target of Smyd1 through RNA-seq. Chromatin immunoprecipitation assay showed that Smyd1 directly interacts with the promoter of Perm1 in the mouse heart, and this interaction was significantly reduced in mouse hearts failing due to pressure overload for 4 weeks, where Perm1 was downregulated (24.4 ± 5.9% of sham, p<0.05). Similarly, the Perm1 protein level was significantly decreased in patients with advanced heart failure (55.2 ± 13.1% of donors, p<0.05). Phenylephrine (PE)-induced hypertrophic stress in cardiomyocytes also led to downregulation of Perm1 (55.7 ± 5.7% of control, p<0.05), and adenovirus-mediated overexpression of Perm1 rescued PE-induced downregulation of estrogen-related receptor alpha (ERRα), a key transcriptional regulator of mitochondrial energetics, and its target gene, Ndufv1 (Complex I). Pathway enrichment analysis of cardiomyocytes in which Perm1 was knocked-down by siRNA (siPerm1), revealed that the most downregulated pathway was metabolism. Cell stress tests using the Seahorse XF analyzer showed that basal respiration and ATP production were significantly reduced in siPerm1 cardiomyocytes (40.7% and 23.6% of scrambled-siRNA, respectively, both p<0.05). Luciferase reporter gene assay further revealed that Perm1 dose-dependently increased the promoter activity of the ERRα gene and known target of ERRα, Ndufv1 (Complex I). Overall, our study demonstrates that Perm1 is an essential regulator of cardiac energetics through ERRα, as part of the Smyd1 regulatory network.